Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company based in Lexington, Mass. It creates medicines through a scientific approach utilizing the naturally occurring element deuterium. Concert Pharmaceuticals Inc. has raised $110 million since its inception. The company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS, and renal disease, among others. USPTO granted Concert Pharmaceutical s first patents in 2009. Some of the company s investors include Brookside Capital Partners Fund, TVM Capital, Three Arch Partners, Fidelity Investments, Skyline Ventures, Flagship Ventures, Adage Capital Management and New Leaf Venture Partners.
Partial Data by Infogroup (c) 2024. All rights reserved.